z-logo
Premium
A model for mapping the fate of CD8+ T cells that have expressed granzyme B (GzmB)
Author(s) -
Bannard Oliver Michael,
Fearon Douglas
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.846.19
Subject(s) - biology , cytotoxic t cell , cd8 , microbiology and biotechnology , granzyme b , effector , lymphocytic choriomeningitis , ctl* , immunology , cancer research , in vitro , immune system , genetics
Commitment to effector differentiation of the CD8+ T cell may be associated with senescence. To define when this occurs, it is necessary to indelibly mark a cell during development and follow its fate without artificial interventions. We have generated a BAC transgenic mouse line that expresses a tamoxifen‐regulated Cre/ERT2 recombinase controlled by transcriptional elements of the effector gene, Gzmb . Crossing these mice with the R26R‐EYFP Cre reporter line permits conditional, permanent expression of EYFP in cells that had transcribed Gzmb . Stimulation in vitro under GzmB‐inducing conditions caused expression of EYFP in up to 50% of GzmB+ CD8+ T cells from these mice, only in GzmB+ cells, and only with tamoxifen. Influenza infection caused tamoxifen‐dependent EYFP expression by 21% and 31% of nucleoprotein (NP)‐specific CD8+ T cells in the spleen and lung, all of which were GzmB+. Six weeks post‐infection the splenic number decreased to 15%, all EYFP+ cells were now GzmB−, and were CD62L high or low. After secondary infection without tamoxifen, the number of EYFP+ CD8+ T cells in the lung increased ∼100‐fold, indicating a capacity for clonal expansion despite prior expression of GzmB. Thus, we now have a model with which we can map the fate of CD8+ T cells that have transcribed Gzmb at a specified time during repetitive or persistent viral infections, irrespective of continued expression of the gene. Wellcome Trust.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here